Free tool
FAERS Monitor: Mitosol
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022572 or its brand name (Mitosol, Mitomycin). Reports on generic versions are filed under their own applications.
Reports
2,564
Serious
2,416
94% of reports
Hospitalization
857
Death reported
377
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use364
- diarrhoea152
- nausea132
- thrombocytopenia107
- neutropenia106
- drug ineffective101
- disease progression98
- pancytopenia93
- vomiting89
- fatigue78
- death76
- leukopenia74
- febrile neutropenia71
- pyrexia67
- malignant neoplasm progression65
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 67 |
| 2005 | 77 |
| 2006 | 86 |
| 2007 | 96 |
| 2008 | 125 |
| 2009 | 79 |
| 2010 | 94 |
| 2011 | 137 |
| 2012 | 134 |
| 2013 | 129 |
| 2014 | 95 |
| 2015 | 115 |
| 2016 | 98 |
| 2017 | 87 |
| 2018 | 127 |
| 2019 | 160 |
| 2020 | 152 |
| 2021 | 126 |
| 2022 | 89 |
| 2023 | 74 |
| 2024 | 133 |
| 2025 | 177 |
| 2026 | 107 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,595 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pancytopeniaSignal | 93 | 13.7 | 11.2 | 1,081 |
| leukopeniaSignal | 74 | 12.2 | 9.7 | 747 |
| febrile neutropeniaSignal | 71 | 8.8 | 7.0 | 483 |
| thrombocytopeniaSignal | 107 | 7.9 | 6.5 | 636 |
| disease progressionSignal | 98 | 6.8 | 5.6 | 481 |
| neutropeniaSignal | 106 | 6.4 | 5.3 | 480 |
| malignant neoplasm progressionSignal | 65 | 5.2 | 4.1 | 218 |
| off label useSignal | 364 | 3.4 | 3.1 | 644 |
| diarrhoea | 152 | 1.9 | 1.7 | 70 |
| pyrexia | 67 | 1.6 | 1.3 | 14 |
| vomiting | 89 | 1.6 | 1.3 | 17 |
| nausea | 132 | 1.4 | 1.2 | 13 |
| fatigue | 78 | 0.8 | 0.7 | 3 |
| death | 76 | 0.7 | 0.6 | 8 |
| drug ineffective | 101 | 0.6 | 0.5 | 23 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.